Status:
UNKNOWN
Myopia Progression and the Effect of 7-Methylxanthine
Lead Sponsor:
Trier Research Laboratories
Collaborating Sponsors:
Generalkonsul Einar Høyvalds Fond
Jørgen Bagenkop Nielsens Myopi-Fond
Conditions:
Myopia
Eligibility:
All Genders
8-13 years
Phase:
PHASE2
Brief Summary
7-methylxanthine has been shown to increase the concentration and thickness of collagen fibrils in rabbit sclera. Deficient collagen in the sclera may be the cause of progression of childhood myopia. ...
Detailed Description
Participants are given tablets of 7-methylxanthine 400 mg per day or placebo tablets for 12 months. Axial length, cycloplegic refraction and corneal curvature is measured, as well as weight, height, b...
Eligibility Criteria
Inclusion
- Children in the age 8-13 years with myopia and an axial growth rate of 0.15 mm or more per year.
- \-
Exclusion
- Severe general ailment (for example diabetes, epilepsy, psychiatric disease) Eye diseases (for example cataract, keratoconus, chronic iritis, glaucoma)
- \-
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
End Date :
March 1 2006
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT00263471
Start Date
October 1 2003
End Date
March 1 2006
Last Update
December 14 2005
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.